Cargando…

1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience

BACKGROUND: Invasive mold infections (IMIs) remain a significant cause of morbidity and mortality in patients with acute leukemia (AL) and those undergoing hematopoietic stem cell transplantation (HSCT). We describe the epidemiology of IMIs, the incidence of IMI in patients with acute myelogenous Le...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubat, Ryan, Subramanian, Praveen, Li, Yanming, Hammoud, Kassem, Eid, Albert, Dias, Ajoy, El Atrouni, Wissam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776790/
http://dx.doi.org/10.1093/ofid/ofaa439.1339
_version_ 1783630764049432576
author Kubat, Ryan
Subramanian, Praveen
Li, Yanming
Hammoud, Kassem
Eid, Albert
Dias, Ajoy
El Atrouni, Wissam
author_facet Kubat, Ryan
Subramanian, Praveen
Li, Yanming
Hammoud, Kassem
Eid, Albert
Dias, Ajoy
El Atrouni, Wissam
author_sort Kubat, Ryan
collection PubMed
description BACKGROUND: Invasive mold infections (IMIs) remain a significant cause of morbidity and mortality in patients with acute leukemia (AL) and those undergoing hematopoietic stem cell transplantation (HSCT). We describe the epidemiology of IMIs, the incidence of IMI in patients with acute myelogenous Leukemia (AML) post HSCT, and risk factors for mortality. METHODS: Patients were identified using ICD9 and ICD10 codes using a University of Kansas internal database from 2009-2019, microbiology records, and an AML HSCT database and were followed through May 1(st), 2020. Patients’ electronic medical records were reviewed for inclusion. IMI was defined as proven or probable using the 2009 National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) guidelines. Incidence was calculated as IMI cases/100-person-years. Risk factors for overall mortality were evaluated using a Cox regression model. RESULTS: We included 138 patients: 79 developed IMI after HSCT (8 autologous, 71 allogeneic) and 59 developed IMI after AL diagnosis. Seventeen of the AL patients underwent HSCT after IMI diagnosis (12 within 100 days of IMI). Proven IMI occurred in 45 (32.6%) and probable IMI occurred in 93 (67.4%) patients. The most common prophylactic agent prior to IMI diagnosis was fluconazole (31.2%), with 21.0% receiving none. Aspergillus was the most commonly identified mold with 91 (65.9%) cases. The average treatment duration was 101 (range 0 - 799) days. The incidence of IMI in patients with AML who underwent HSCT was 2.35 cases/100 person-years. All-cause mortality among patients with AL or HSCT who developed IMI was 23.1% at 6 weeks, 34.1% at 12 weeks, and 61.2% at 1 year. On univariate Cox model, Karnofsky performance status > 70 was associated with lower mortality (hazard ratio (HR) 0.317, 95% confidence interval (CI) [0.110, 0.914]) among HSCT recipients. ICU admission within 7 days prior to IMI diagnosis (HR 6.469, 95% CI [1.779, 23.530]) and each one point increase in BMI (HR 1.051, CI [1.001, 1.103]) were associated with increased mortality in the AL group. Figure 1 - Invasive mold infections by pathogen in HSCT-recipients and acute leukemia patients from 2009-2019. [Image: see text] Figure 2 - Antifungal prophylactic agents prescribed for at least one week at time of IMI diagnosis [Image: see text] Table 1 - Univariate survival analysis calculated using a Cox proportional-hazards regression model among patients who developed IMI after HSCT and patients who developed IMI after acute leukemia diagnosis [Image: see text] CONCLUSION: IMIs are associated with significant mortality in HSCT recipients and AL patients; patients at higher risk for mortality include those with lower baseline Karnofsky scores, recent ICU admissions, and higher BMI at time of IMI diagnosis. DISCLOSURES: Wissam El Atrouni, MD, ViiV (Advisor or Review Panel member)
format Online
Article
Text
id pubmed-7776790
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77767902021-01-07 1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience Kubat, Ryan Subramanian, Praveen Li, Yanming Hammoud, Kassem Eid, Albert Dias, Ajoy El Atrouni, Wissam Open Forum Infect Dis Poster Abstracts BACKGROUND: Invasive mold infections (IMIs) remain a significant cause of morbidity and mortality in patients with acute leukemia (AL) and those undergoing hematopoietic stem cell transplantation (HSCT). We describe the epidemiology of IMIs, the incidence of IMI in patients with acute myelogenous Leukemia (AML) post HSCT, and risk factors for mortality. METHODS: Patients were identified using ICD9 and ICD10 codes using a University of Kansas internal database from 2009-2019, microbiology records, and an AML HSCT database and were followed through May 1(st), 2020. Patients’ electronic medical records were reviewed for inclusion. IMI was defined as proven or probable using the 2009 National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) guidelines. Incidence was calculated as IMI cases/100-person-years. Risk factors for overall mortality were evaluated using a Cox regression model. RESULTS: We included 138 patients: 79 developed IMI after HSCT (8 autologous, 71 allogeneic) and 59 developed IMI after AL diagnosis. Seventeen of the AL patients underwent HSCT after IMI diagnosis (12 within 100 days of IMI). Proven IMI occurred in 45 (32.6%) and probable IMI occurred in 93 (67.4%) patients. The most common prophylactic agent prior to IMI diagnosis was fluconazole (31.2%), with 21.0% receiving none. Aspergillus was the most commonly identified mold with 91 (65.9%) cases. The average treatment duration was 101 (range 0 - 799) days. The incidence of IMI in patients with AML who underwent HSCT was 2.35 cases/100 person-years. All-cause mortality among patients with AL or HSCT who developed IMI was 23.1% at 6 weeks, 34.1% at 12 weeks, and 61.2% at 1 year. On univariate Cox model, Karnofsky performance status > 70 was associated with lower mortality (hazard ratio (HR) 0.317, 95% confidence interval (CI) [0.110, 0.914]) among HSCT recipients. ICU admission within 7 days prior to IMI diagnosis (HR 6.469, 95% CI [1.779, 23.530]) and each one point increase in BMI (HR 1.051, CI [1.001, 1.103]) were associated with increased mortality in the AL group. Figure 1 - Invasive mold infections by pathogen in HSCT-recipients and acute leukemia patients from 2009-2019. [Image: see text] Figure 2 - Antifungal prophylactic agents prescribed for at least one week at time of IMI diagnosis [Image: see text] Table 1 - Univariate survival analysis calculated using a Cox proportional-hazards regression model among patients who developed IMI after HSCT and patients who developed IMI after acute leukemia diagnosis [Image: see text] CONCLUSION: IMIs are associated with significant mortality in HSCT recipients and AL patients; patients at higher risk for mortality include those with lower baseline Karnofsky scores, recent ICU admissions, and higher BMI at time of IMI diagnosis. DISCLOSURES: Wissam El Atrouni, MD, ViiV (Advisor or Review Panel member) Oxford University Press 2020-12-31 /pmc/articles/PMC7776790/ http://dx.doi.org/10.1093/ofid/ofaa439.1339 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Kubat, Ryan
Subramanian, Praveen
Li, Yanming
Hammoud, Kassem
Eid, Albert
Dias, Ajoy
El Atrouni, Wissam
1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience
title 1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience
title_full 1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience
title_fullStr 1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience
title_full_unstemmed 1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience
title_short 1153. Characterization of Invasive Mold Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Recipient Patients and Risk Factors for Mortality - a Single Center Experience
title_sort 1153. characterization of invasive mold infections in acute leukemia and hematopoietic stem cell transplant recipient patients and risk factors for mortality - a single center experience
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776790/
http://dx.doi.org/10.1093/ofid/ofaa439.1339
work_keys_str_mv AT kubatryan 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience
AT subramanianpraveen 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience
AT liyanming 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience
AT hammoudkassem 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience
AT eidalbert 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience
AT diasajoy 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience
AT elatrouniwissam 1153characterizationofinvasivemoldinfectionsinacuteleukemiaandhematopoieticstemcelltransplantrecipientpatientsandriskfactorsformortalityasinglecenterexperience